Psychedelic Trial Veterans Reveal What Clinical Trials Get Wrong About Healing

For people who have spent years cycling through antidepressants, therapy and psychiatric wards, the chance to join a psychedelic clinical trial can feel like a last resort wrapped in hope. But what actually happens inside those trials, from the first screening phone call to the day the study ends, has rarely been examined through the eyes of the people who lived it. Now a qualitative study published in Frontiers in Psychiatry has done exactly that, gathering former psychedelic trial participants from the Psychedelic Participant Advocacy Network (PsyPAN) to map their experiences across recruitment, preparation, dosing, integration and study ending, and to generate concrete recommendations for future trials and treatment delivery.

The research team, led by Mathieu Seynaeve of Beckley Psytech Ltd. and King’s College London, worked with four PsyPAN members who had all completed psychedelic clinical trials in the United Kingdom. Three had joined treatment-resistant depression studies involving psilocybin or N,N-dimethyltryptamine (DMT), while one had taken part in a psilocybin study for an eating disorder. The participants completed three remote focus groups organized chronologically around the phases of trial participation, followed by a one-day in-person workshop to review the analysis and develop recommendations. The findings were then refined with input from the wider PsyPAN network, which represents more than seventy former trial participants. The analysis, informed by reflexive thematic analysis, produced five themes that together reveal a striking tension between what participants sought and what clinical trials were designed to deliver.

The first theme is perhaps the most fundamental: participants entered trials seeking potentially effective treatment, but encountered a clinical trial. The distinction sounds semantic, but it shapes everything. People arriving after eighteen years of contact with mental health services, multiple medications and countless therapy modalities hoped to access a novel intervention. Instead, they met procedures shaped by eligibility criteria, equipoise, randomization, blinding, standardization, fixed schedules and endpoint-driven evidence generation. Screening proved particularly stressful. Participants described prolonged uncertainty about eligibility and perceived screening teams as focused on excluding rather than including them, forcing them to second-guess what the team wanted. One participant described trying to make their case while balancing demonstration of symptom severity against perceived risk, a fine line between someone who needs this and someone so unwell they would be taking a massive risk.

Communication failures compounded the strain. One participant applied to a trial and heard nothing for nine months, describing the silence as particularly damaging because people reach out in desperation. Another, deemed ineligible, recounted disappointment and despair amplified by limited clarity about the reasons, feeling like a distant administrative team rather than caring people who wanted to make sure you were okay. The participants also noted that the burden of participation, including time, travel and repeated appointments, effectively narrows who can take part, pricing out those on low incomes or with family commitments and keeping the trial population demographically narrow.

The second theme extends the well-known concept of set and setting to the clinical-trial context. Set refers to the participant’s internal state, including expectations, fears and preparation, while setting refers to the physical and social environment of dosing. The participants argued that the creation of a supportive setting begins with the very first contact with potential participants, even during boring paperwork, because that is where trust building starts. Research-specific conditions, including treatment-allocation uncertainty, communication quality, staff conduct, time-limited support and study ending, all shaped experience and could either exacerbate or mitigate the tension between treatment-seeking and research requirements. Managing expectations emerged as a critical preparation task. Participants recommended education about the full range of possible dosing experiences, from intense to subtle to placebo-like non-experiences, and warned against equating higher doses with more intense experiences or more intense experiences with greater therapeutic value. One participant who received three ascending doses had an extremely intense experience on the lowest dose, attributing the depth of the experience to the trust felt in the sitters.

The third theme positions facilitators as mediators between protocol requirements and participants’ embodied, relational and psychological needs, particularly during dosing. Participants valued facilitators’ calm, non-directive presence, describing them as guides who knew the territory rather than medical experts who knew the way to a cure. Building sufficient trust to be vulnerable during dosing required time, and for some participants with histories of childhood adversity, the limited preparation window posed real difficulties. Physical touch emerged as a nuanced topic. Participants distinguished consent and boundaries, the embodied or symbolic function of touch, and the meaning of touch being withheld or removed. For some, well-timed and sensitive touch enhanced safety and supported engagement with challenging or preverbal material, while one participant felt touch had not been offered sufficiently during their studies. The group agreed that video recording sessions was an acceptable safeguard, preferred over not using physical touch at all.

The fourth theme reframes dosing itself: participants experienced it not as a discrete event but as the beginning of an ongoing process of meaning-making, change and integration. Processing began as acute effects subsided and continued well beyond the final study visit. Changes arose non-linearly, ranging from symptom improvement and wellbeing to emotional openness, psychological flexibility and shifts in perspective. Some participants experienced disappointment when expected benefits did not occur or initial improvements faded, and several felt they had let the study team down, resulting in shame. Supportive integration sessions helped participants reframe these challenges. Practical tools for integration included journaling, movement, creative expression, nature connection, playlists and guided meditations. Participants also emphasized involving their support networks more actively, providing tangible resources for families so that loved ones could help without participants having to explain everything themselves.

The fifth theme addresses what happens after the trial ends, and it is here that the unmet need is starkest. Some participants described loss, grief or frustration when significant attachment bonds with facilitators ended, while all reported that further structured support would have been beneficial. Access to psychedelically informed therapists proved limited by cost, and returning to pre-existing mental health support often felt insufficient. When symptoms returned and no formal route back into the treatment model existed, some participants described desperation and considered self-medicating, while recognizing that this would not recreate the supportive context of the study. The participants therefore advocated dedicated, independent, trial-specific peer-support aftercare spaces, arguing that connection with others who had gone through the same clinical trial process is unique and important in ways that ordinary integration groups cannot replicate.

The recommendations generated from these themes are extensive and participant-informed. They emphasize clear communication from first contact, realistic expectation management, explicit distinction between research and treatment frames, reduced avoidable burden, staff continuity across study phases, participant agency within protocol-defined boundaries, boundaries around touch and movement, involvement of support networks with consent, and deliberate planning for integration and study ending. The authors note that not all recommendations can be met within rigorous randomized controlled trial designs, given scientific, regulatory and resource constraints, but that many can inform post-approval psychedelic-assisted therapies and enhance acceptability, efficacy and safety in practice.

The study has limitations that the authors acknowledge candidly. The sample was small, self-selected and demographically narrow, consisting of four white participants from UK trials, and the findings cannot represent the full range of participant experiences, including those who failed screening, withdrew, had strongly negative experiences or did not become involved in advocacy. The retrospective focus-group format may have encouraged convergence, and the study was initiated as part of a patient and public involvement initiative by a company developing psychedelic treatments, though none of the participants had taken part in a study sponsored by that company. Nevertheless, the study represents a rare systematic effort to place the participant voice at the center of psychedelic trial design. As the field moves from small proof-of-concept studies toward multi-site phase 2 and phase 3 programs that could bring psychedelic treatments to regulatory approval in the coming years, the experiences of those who have already walked the path suggest that the relational, contextual and systemic factors surrounding the drug matter as much as the drug itself, and that structured post-study peer support may be essential to address continuing needs after trial completion.

Subject of Research: Health

Article Title: Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network

Article References: Seynaeve, M., Schneider, L., Roullier, I., Lazenby, K., Lilley, C., Lobo, S., Ermakova, A. O., Wells, H., Cleare, A., & Rucker, J. (2026). Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network. Frontiers in Psychiatry, 17, Article 1682810. https://doi.org/10.3389/fpsyt.2026.1682810

Image Credits: AI Generated

DOI: 10.3389/fpsyt.2026.1682810

Keywords: psychedelics, clinical trials, psilocybin, DMT, mental health, depression, qualitative research, Participant, experiences, recommendations, psychedelic, clinical